Markets

Johnson & Johnson: Down But Not Out

Shares of this diversified health care company have stumbled, but some analysts say long-term investors needn't worry.

The share price of Johnson Johnson (symbol JNJ) has fallen more than 15% from its 52-week high, reached last April. This week's news hasn't helped matters: A disappointing fourth-quarter sales report on Tuesday was followed Wednesday with word that the company had lost its battle with Boston Scientific to acquire medical-device maker Guidant.

Analysts acknowledge that the company faces some near-term challenges, but some, including SG Cowen's Sara Michelmore, say that its beaten-down shares could be appealing, especially for long-term investors. At $59, the stock trades at 16 times the $3.68 per share that analysts estimate JJ will earn in 2006, according to Thomson First Call.

Citigroup analyst Matthew Dodds notes that JJ's fourth-quarter sales were below plan across the board. JJ operations are divided into three divisions -- drugs, consumer products, and medical devices and diagnostics. And "all three divisions looked wobbly," he says. But he doesn't think that the health care giant's problems are catastrophic.

JJ's "financial performance should still improve as we move through 2006," he says. In particular, he says that the company's large pharmaceutical segment -- which has been going through a rough patch -- should start to enjoy solid sales the second half of this year, helped by growth in existing drugs as well as promising products now in its pipeline.

Despite lower-than-expected sales, JJ still met earnings expectations of 73 cents per share in the fourth quarter.

The purchase of Guidant would have allowed JJ to further build up its medical-device business, which makes drug-eluding stents, among other products. But the bidding war with Boston Scientific had pushed up Guidant's price, and Standard Poor's analyst Robert Gold figures JJ was smart to bow out when it did. With the deal no longer on the table, he says, JJ will likely look for another acquisition to drive growth. He sees growth in the medical-device division as critical to JJ's prospects, and continues to recommend the stock.

JJ has increased its dividend consistently for more than 40 years. The stock yields 2.2%.

--Lisa Dixon

Most Popular

When Could We Get a Third Stimulus Check?
Coronavirus and Your Money

When Could We Get a Third Stimulus Check?

President Biden and others in Congress are pushing for a third-round of stimulus checks, but it might be a while before we get them.
January 20, 2021
Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer
Coronavirus and Your Money

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer

The IRS has an online tool that lets you track the status of your second stimulus check.
January 18, 2021
20 Best Stocks to Buy for the Joe Biden Presidency
stocks to buy

20 Best Stocks to Buy for the Joe Biden Presidency

Joe Biden has been sworn in as America's 46th president. These are 20 of the best stocks to own under the new administration.
January 20, 2021

Recommended

The Best and Worst Presidents (According to the Stock Market)
Markets

The Best and Worst Presidents (According to the Stock Market)

Which American presidents oversaw the best stock market performances? Just for grins, let's see what a 'stock market Mount Rushmore' might look like.
January 19, 2021
Is the Stock Market Open on Inauguration Day 2021?
Markets

Is the Stock Market Open on Inauguration Day 2021?

The federal government will enjoy an off day on Inauguration Day, but the stock and bond markets alike will conduct business as usual.
January 19, 2021
5 Danger Signs That You’re an ‘Immature’ Investor
investing

5 Danger Signs That You’re an ‘Immature’ Investor

To make the most of your investments, you need to think about them in the right way. Investing immaturity can hold you back from reaching the next lev…
January 11, 2021
James K. Glassman’s Stock Picks for 2021
Kiplinger's Investing Outlook

James K. Glassman’s Stock Picks for 2021

Kiplinger columnist James K. Glassman has been picking 10 stocks a year for decades now. We talk about what’s on his 2021 list, and how previous picks…
January 7, 2021